"I have seen first-hand the drive and heart that CGT personnel bring to their work and the weight that rigorous training and collaboration carries in advancing CGT. My conversations with our team frequently touch on the opportunity to play a role in producing life-changing therapies for patients, which is a big motivator for them." Daniel Palmacci, Head of Specialized Modalities at Lonza, recently wrote an article for The Medicine Maker about how mentorship, professional development and open dialogue help build resilient cell and gene therapy teams. Read the full article here: https://lnkd.in/dtvXReT9
Daniel your article perfectly captures the spirit and resilience needed to thrive in CGT—and it’s clear Lonza is setting the standard. I’ve seen that same passion and purpose in action, and it’s inspiring to imagine the impact we could make together by combining that drive with Lonza’s visionary leadership in the space.
--
2dLove this